Asset profile
NPT2042
Small molecule
Evidence outlook · lead readout
NCT05503511 · Epilepsy, Alzheimer Disease, Epilepsy Intractable
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05503511: Participants were randomized to active drug or matching placebo under blinded conditions across escalating single- and multi-day dose cohorts, but results have not been posted, so no comparison of adverse-event or lab-abnormality rates between groups is available yet.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
August 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.